A new journal has been published by the National Library of Medicine for ANZGOG’s MOST-S26 study.
The Measure of Ovarian Symptoms and Treatment study (MOST-S26) detected an improvement in symptoms of peripheral neuropathy, psychological distress and may detect symptoms of relapse for women with ovarian cancer.
The administration of MOST-S26 acts to complement the clinical follow-up of patients to identify concerning symptoms and facilitate timely and appropriate intervention, after the completion of first-line treatment.
ANZGOG member and co-author of the publication, Dr Rachel Campbell, discusses the study publication:
“This paper describes the development and validation of the MOST-S26, a patient-reported outcome measure designed for surveillance of symptoms following first-line chemotherapy for ovarian cancer. MOST-S26 assesses physical symptoms likely due to treatment or recurrent disease, psychological symptoms, and well-being.
MOST-S26 detected improvements in peripheral neuropathy and psychological distress approximately 12 months post-treatment and a worsening of abdominal symptoms within three months of a clinically diagnosed recurrence. MOST-S26 has the potential to be used as part of the routine follow-up to identify persistent treatment-related side effects and psychological distress, trigger early referral for appropriate management, and perhaps facilitate earlier detection of symptoms of recurrence.”
Dr Rachel Campbell
Post-doctoral Fellow at The University of Sydney
